Peptide Advocate
Back to News

/ Peptide Advocate

FDA-Approved7/10 · Recommended

Tesamorelin: The Growth Hormone Peptide That Earned FDA Approval

Most growth hormone peptides you’ll hear about online have never been approved for anything. Tesamorelin is the exception: an FDA-approved medicine that cut deep belly fat by 14–18% in large clinical trials. Here’s how it works, who it’s for, what to expect, and the promising new research on fatty liver and memory.

Tesamorelin: the growth hormone peptide that earned FDA approval

Most growth hormone peptides you'll hear about online have never been approved for anything. Tesamorelin is the exception. It's an FDA-approved medicine with solid clinical trials behind it, and new research suggests it may do even more. Here's what it does, who it's for, what to expect, and what the science says about its newer uses.

Peptide Advocate · Research explainer · Updated October 2026

What it isA lab-made version of GHRH, the brain signal that tells your body to release its own growth hormone1
Approved forReducing excess belly fat in adults with HIV and lipodystrophy, sold as Egrifta WR (previously Egrifta SV)1,2
How well it worksCut deep belly fat by 14–18% in 26 weeks in two large trials, while placebo barely changed1
Good to knowIt's a daily injection, benefits fade if you stop, and blood sugar needs monitoring1

What is tesamorelin?

Tesamorelin is a stabilized copy of GHRH (growth hormone-releasing hormone), the signal your brain uses to tell the pituitary gland to release growth hormone.1 Instead of supplying growth hormone directly, it prompts your body to make more of its own, which then raises IGF-1, the hormone that carries out many of growth hormone's effects.

The FDA first approved it in 2010 as Egrifta. In March 2025, the FDA approved a newer version, Egrifta WR, which still requires a daily injection but only needs to be mixed once a week, uses less than half the injection volume, and can be stored at room temperature.2

How it compares to other growth hormone peptides

PeptideHow it worksFDA-approved?Best human evidence
TesamorelinCopies GHRH; daily injectionYes, for HIV-related belly fatTwo large Phase 3 trials, plus newer liver and memory studies1,4,5
CJC-1295Copies GHRH; lasts about a weekNoShort 2006 hormone studies; development stopped
IpamorelinMimics ghrelinNoOne Phase 2 trial that missed its main goal

See our CJC-1295 and ipamorelin explainers for details on those peptides.

Why it was approved: the belly fat results

Some people living with HIV develop lipodystrophy, a shift in body fat that can build up visceral fat, the deep fat packed around the organs. Visceral fat is linked to heart and metabolic disease, and it can be hard to lose with diet and exercise alone. Tesamorelin was tested in two Phase 3 trials with more than 800 people, first published in the New England Journal of Medicine in 2007.1,3

Belly fat went down, placebo didn'tAverage change in visceral (deep belly) fat after 26 weeks, two Phase 3 trialsStudy 1−18%Tesamorelin+2%PlaceboStudy 2−14%Tesamorelin−2%PlaceboBars to the left of the line mean fat was lost. Treatment difference: 20% (Study 1) and 12% (Study 2).
Source: Egrifta WR prescribing information, Studies 1 and 2.1 Measured by CT scan.

Importantly, tesamorelin targets belly fat without being a weight-loss drug: the label describes it as weight-neutral, and it isn't approved for weight loss.1

2010year the FDA first approved tesamorelin1
14–18%average drop in deep belly fat after 26 weeks1
37%relative reduction in liver fat in a 2019 trial of people with HIV and fatty liver4
1×/weekmixing needed with the newer Egrifta WR (injections are still daily)2

The catch: you have to keep taking it

In the trials, people who responded to tesamorelin were split into two groups after 26 weeks: one kept taking it and one switched to placebo. The difference was clear.1

Benefits last only while you take itChange in visceral fat from week 26 to week 52 in people who had responded to tesamorelinStudy 10%Kept taking it+22%Switched to placeboStudy 2−5%Kept taking it+16%Switched to placeboPeople who stopped quickly regained belly fat, while those who continued kept their results.
Source: Egrifta WR prescribing information, extension phases of Studies 1 and 2.1

That's typical for medicines that treat ongoing conditions, like blood pressure or cholesterol drugs. It's worth knowing before starting, since tesamorelin is a daily injection.

Exciting newer research

Because tesamorelin is approved and well characterized, researchers have been able to test it in carefully designed trials for other conditions. Two stand out:

Tesamorelin and fatty liver In a 12-month trial of 61 people with HIV and fatty liver disease, 35 percent of people on tesamorelin reached normal liver fat versus 4 percent on placebo. Two people on tesamorelin had fibrosis develop or worsen, versus nine on placebo. A promising result for fatty liver 12-month trial in 61 people with HIV and fatty liver disease (2019) Reached normal liver fat TesamorelinPlacebo 35% 4% Liver scarring (fibrosis) developed or worsened TesamorelinPlacebo 2 people9 people
Source: Stanley et al., The Lancet HIV, 2019, as summarized by HIV.gov Clinical Info.4
  • Fatty liver. In the 2019 trial above, tesamorelin cut liver fat by 37% in relative terms and appeared to slow scarring. Fatty liver disease is common in people with HIV, and this is one of the more exciting findings for any growth hormone-related peptide.4
  • Memory and thinking. In a 2012 trial of 152 older adults, 66 of them with mild cognitive impairment, 20 weeks of tesamorelin improved executive function (planning and focus) and verbal memory in both groups compared to placebo.5

Keep in mind: these are promising, but they're single trials, and tesamorelin isn't FDA-approved for fatty liver or memory. Larger studies would be needed before either becomes a standard use.

Side effects and safety

Because tesamorelin went through full FDA review, its side effects are well documented. Most are mild. Here are the ones reported more often than with placebo during the first 26 weeks:1

Side effectTesamorelinPlacebo
Injection site reactions (redness, itching)17%6%
Joint pain13%11%
Muscle pain6%2%
Swelling in the legs or feet6%2%
Pain in arms or legs6%5%
Tingling (paresthesia)5%2%
Reduced sensation (hypoesthesia)4%2%
Rash4%2%

A few things your doctor will watch for:1

  • Blood sugar. Tesamorelin can raise blood sugar. In the trials, 5% of people on it developed diabetes-range blood sugar (HbA1c of 6.5% or higher) by week 26, versus 1% on placebo. Your doctor will check your levels before and during treatment.
  • IGF-1 levels. Because tesamorelin raises IGF-1, doctors monitor it and may stop treatment if levels stay high.
  • Fluid retention. Swelling, joint pain or carpal tunnel symptoms can happen. They're usually temporary or go away after stopping.
  • Allergic reactions. These occurred in about 4% of people. Stop and call your doctor if you notice hives, swelling or trouble breathing.

Who shouldn't take tesamorelin

  • People who are pregnant
  • People with an active cancer
  • People with pituitary problems, such as a pituitary tumor, past pituitary surgery, or head radiation or trauma
  • Anyone with a known allergy to tesamorelin1

Also note: long-term heart safety hasn't been established.1 And for athletes, tesamorelin is banned at all times by the World Anti-Doping Agency as a growth hormone-releasing factor.7

What about off-label and wellness use?

Tesamorelin's success has made it popular in wellness and anti-aging clinics. A few things are worth knowing:

  • Off-label use is legal, but unproven. Doctors can legally prescribe an approved drug for other uses. But tesamorelin hasn't been tested for general anti-aging, muscle building or weight loss, and the label specifically says it isn't for weight loss.1,6
  • Insurance rarely covers off-label use, and the brand-name product can be expensive.6
  • Compounded versions are restricted. Because an approved product exists, pharmacies generally can't make copies of it without a documented medical reason.6
  • Skip "research use only" products. They aren't made to drug standards, and you lose the quality guarantees that come with the approved medicine.

If you're interested in tesamorelin

  • Talk to your HIV provider if you have HIV and are concerned about belly fat. Tesamorelin is a proven option, and your provider can check whether it's right for you.
  • Get baseline labs. Blood sugar and IGF-1 should be checked before starting and during treatment.
  • Plan for the long term. Results last only while you keep taking it.
  • Ask about the newer formulation. Egrifta WR only needs mixing once a week, which many people find easier.
  • Be cautious about off-label claims for anti-aging or weight loss, which haven't been studied.

The bottom line

Tesamorelin shows what a growth hormone peptide looks like when it goes through the full scientific process. It has large, well-designed trials, a clear FDA-approved use, a well-documented side-effect profile, and promising new research in fatty liver disease and memory. For adults with HIV-related belly fat, it's a proven, effective treatment. For everyone else, it's a reminder of why rigorous trials matter, and a peptide to keep watching as the research grows.

References

  1. Theratechnologies. Egrifta WR (tesamorelin for injection) prescribing information; revised March 2025. accessdata.fda.gov
  2. Theratechnologies. Theratechnologies receives FDA approval for Egrifta WR; March 25, 2025. sec.gov
  3. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359–2370. natap.org
  4. Drug reverses signs of liver disease in people living with HIV (summary of Stanley TL, et al. Lancet HIV. 2019). HIV.gov Clinical Info. clinicalinfo.hiv.gov
  5. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012. Summary: mdedge.com
  6. Is tesamorelin legal? FDA status and regulations explained (2026). MyPeptideMatch. mypeptidematch.com
  7. World Anti-Doping Agency. Prohibited List, section S2 (growth hormone-releasing factors). wada-ama.org

This article is for general education and is not medical advice. Tesamorelin is a prescription medicine approved by the FDA only to reduce excess abdominal fat in adults with HIV and lipodystrophy. Talk with a licensed healthcare provider about whether it's right for you. This article does not provide dosing instructions. Information is current as of October 16, 2026. Charts and illustrations are original works by Peptide Advocate.

Peptides Referenced

Tesamorelin

Growth Hormone Releasing Hormone

FDA-approved GHRH analog that reduces visceral adipose tissue and supports lean body composition.